Novo agrees $2.6B deal for Hengrui’s preclinical GLP-1/GIP drug
Novo’s ongoing attempts to rejuvenate its pipeline have seen the Big Pharma turn to one of the most…
China’s ‘landmark’ drug pricing guidelines widen biotech profit window: analysts
The State Council, China’s cabinet, has published guidelines on innovative drug pricing that a bank analyst has described…